Latest news
Competitiveness and Excellence Co-operations (VKE)
Genetic predisposition and life style management contribute to the development of type 2 diabetes mellitus (T2DM).
05/10/2018
Latest news
Poster in the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Avidin is presenting a poster in collaboration with Sanders-Brown Center on Aging, University of Kentucky at the AD/PDTM 2017 meeting, the 13th International Conference on
29/03/2017
Successful H2020 grant
Avidin as part of a European consortium leaded by the Burgos University (Spain) successfully won a H2020 grant (PHC-14-2015) entitled „Novel therapeutic approaches for the
01/01/2016
AVIDIN’s Miniconference & Workshop
MINICONFERENCE & WORKSHOP [alert type=”success”]06/07/2015[/alert] Avidin organized a Miniconference & Workshop entitled “TOP LIFE SCIENCE METHODS – Label-free and traditional methods to analyze cellular response
06/07/2015
New Product – SingleCellProtect
SingleCellProtectTM (Cat# SCP-50, SCP-250) solution is an aqueous, nontoxic reagent that induces cell lysis, stabilizes and protects cellular RNA. It is compatible with reverse transcription,
02/02/2015
New Products – MycoKill, MycoQuant
In cell culturing mycoplasma contamination is a major problem regarding both research and industrial production. Unlike fungal or bacterial infections, mycoplasmal contaminations cannot be detected
05/01/2015
New Patent by IP Australia
New patent, entitled ‘8 Hidroxy-Quinoline Derivatives’ was granted by the Australian Patent Office under patent number 2011256989 on 4th December 2014.
04/12/2014
New Patent by US Patent Office
New patent, entitled ‘8 Hidroxy-Quinoline Derivatives’ was granted by the US Patent Office under patent number US 8,871,937 B2 on 28th October 2014.
28/10/2014